Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 4/2009

01-04-2009 | Review Article

Drug Interactions with New and Investigational Antiretrovirals

Authors: Kevin C. Brown, Sunita Paul, Dr Angela D. M. Kashuba

Published in: Clinical Pharmacokinetics | Issue 4/2009

Login to get access

Abstract

More than 20 individual and fixed-dose combinations of antiretrovirals are approved for the treatment of human immunodeficiency virus (HIV) infection. However, owing to the ongoing limitations of drug resistance and adverse effects, new treatment options are still required. A number of promising new agents in existing or new drug classes are in development or have recently been approved by the US FDA. Since these agents will be used in combination with other new and existing antiretrovirals, understanding the potential for drug interactions between these compounds is critical to their appropriate use. This article summarizes the drug interaction potential of new and investigational protease inhibitors (darunavir), non-nucleoside reverse transcriptase inhibitors (etravirine and rilpivirine), chemokine receptor antagonists (maraviroc, vicriviroc and INCB 9471), integrase inhibitors (raltegravir and elvitegravir) and maturation inhibitors (bevirimat).
Literature
1.
2.
De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005 Jun; 49(6): 2314–21PubMedCrossRef
3.
Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007 Dec; 81(24): 13845–51PubMedCrossRef
4.
Sekar V, Spinosa-Guzman S, Lefebvre E, et al. Clinical pharmacology of TMC114 — a potent HIV protease inhibitor [abstract no. TUPE0083]. XVI International AIDS Conference; 2006 Aug 13–18; Toronto (ON)
5.
Sekar V, De Meyer S, Vangeneugden T, et al. Pharmacokinetic/pharmacodynamic analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)
6.
Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999 Sep 10; 13(13): 1623–7PubMedCrossRef
7.
Lee LS, Soon GH, Shen P, et al. Efavirenz increases MRP1 efflux transporter function while darunavir inhibits MRP1 expression in healthy volunteers [abstract no. 705]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8–11; Montreal (QC)
8.
Molina JM, Hill A. Darunavir (TMC114): a new HIV-1 protease inhibitor. Expert Opin Pharmacother 2007 Aug; 8(12): 1951–64PubMedCrossRef
9.
Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007; 46(9): 739–56PubMedCrossRef
10.
TMC114 investigator’s brochure. 7th ed. Co Cork, Ireland: Tibotec, 2006
11.
Sekar, V, Guzman S, Stevens T, et al. Absolute bioavailability of TMC114 administered in the absence and presence of low-dose ritonavir [abstract no. 86]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr 20–22; Lisbon
12.
Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007 Apr; 47(4): 479–84PubMedCrossRef
13.
Busse KH, Penzak SR. Darunavir: a second-generation protease inhibitor. Am J Health Syst Pharm 2007 Aug 1; 64(15): 1593–602PubMedCrossRef
14.
Sekar VJ, Lefebvre E, Mariën K, et al. Pharmacokinetic interaction between the HIV protease inhibitors TMC114 and saquinavir, in the presence of low-dose ritonavir [abstract no. 959]. 44th Annual Meeting of the Infectious Disease Society of America; 2006 Oct 12–15; Toronto (ON)
15.
Sekar VJ, Lefebvre E, Boogaerts G, et al. Pharmacokinetic interaction between the protease inhibitors TMC114 and lopinavir/ritonavir [abstract no. A-367]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
16.
Prezista® (darunavir): summary of product characteristics. London: Janssen-Cilag International NV, 2007
17.
Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol 2008 Jan; 48(1): 60–5PubMedCrossRef
18.
Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother 2007 Mar; 51(3): 958–61PubMedCrossRef
19.
Abel S, Ridgway C, Hamlin J, et al. An open, randomized, 2-way crossover study to investigate the effects of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects [abstract no. 55]. 8th International Workshop on Pharmacology of HIV Therapy; 2007 Apr 16–18; Budapest
20.
Pecini R, Vangeneugden T, Falcon R, et al. Darunavir in combination with other medications: pharmacokinetic interactions [poster no. S3-5]. Presented at the American Conference for the Treatment of HIV (ACTHIV) 2007; 2007 May 31–Jun 3; Dallas (TX)
21.
Sekar V, De Paepe E, Vangeneugden T, et al. Absence of an interaction between the potent HIV protease inhibitor TMC114 and the fusion inhibitor enfuvirtide in the POWER 3 analysis [abstract no. 54]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr 20–22; Lisbon
22.
Sekar VJ, Lefebvre E, Mariën K, et al. Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine, in the presence of low-dose ritonavir [abstract no. 956]. 44th Annual Meeting of the Infectious Disease Society of America; 2006 Oct 12–15; Toronto (ON)
23.
Hoetelmans RM, Mariën K, De Pauw M, et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007 Nov; 64(5): 655–61PubMedCrossRef
24.
Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007 Jul 11; 21(11): 1449–55PubMedCrossRef
25.
26.
Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12(5): 789–96PubMed
27.
Sekar VJ, De Pauw M, Mariën K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 2007; 12(4): 509–14PubMed
28.
29.
Chuck SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert Opin Drug Saf 2002 May; 1(1): 5–17PubMedCrossRef
30.
Sekar VJ, Spinosa-Guzman S, Mariën K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin [abstract no. 55]. 8th International Workshop on Pharmacology of HIV Therapy; 2007 Apr 16–18; Budapest
31.
Sekar VJ, Lefebvre E, Felicione E, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and TMC114, a new protease inhibitor [abstract no. A-368]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
32.
33.
Sekar V, De Paepe E, De Marez T, et al. Pharmacokinetic interaction between TMC114, a new protease inhibitor, and the selective serotonin reuptake inhibitors, paroxetine and sertraline [abstract no. P295]. 8th International Congress on Drug Therapy for HIV; 2006 Nov 12–16; Glasgow
34.
Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection: a review of experimental and clinical data. J Chemother 1999 Apr; 11(2): 107–18PubMed
35.
Rodvold K. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999 Nov; 37(5): 385–98PubMedCrossRef
36.
Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998 Oct; 64(4): 355–62PubMedCrossRef
37.
Brophy DF, Israel DS, Pastor A, et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob Agents Chemother 2000 Apr; 44(4): 978–84PubMedCrossRef
38.
Boruchoff SE, Sturgill MG, Grasing KW, et al. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. Clin Pharmacol Ther 2000 Apr; 67(4): 351–9PubMedCrossRef
39.
Sekar VJ, Lefebvre E, De Pauw M, et al. Pharmacokinetic interaction between TMC114 and ketoconazole, in the absence and presence of low-dose ritonavir [abstract no. 960]. 44th Annual Meeting of the Infectious Disease Society of America; 2006 Oct 12–15; Toronto (ON)
40.
Nadler JP, Berger DS, Blick G, et al., for the TMC125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007 Mar 30;21 (6): F1–10
41.
42.
Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005 Oct; 79(20): 12773–82PubMedCrossRef
43.
Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004 Dec; 48(12): 4680–6PubMedCrossRef
44.
Ramanathan S, West S, Kakuda TN, et al. Lack of clinically relevant drug interactions between ritonavir-boosted elvitegravir and TMC125 [abstract no. H-1049]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
45.
Kakuda TN, Schöller-Gyüre M, Woodfall B, et al. TMC125 in combination with other medications: summary of drug-drug interaction studies [abstract no. PL5.2]. 8th International Congress on Drug Therapy for HIV; 2006 Nov 12–16; Glasgow
46.
Kakuda TN, Kiser JJ. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20–22 April 2006, Lisbon, Portugal. Expert Opin Pharmacother 2006 Aug; 7(11): 1519–33PubMedCrossRef
47.
Israel D, Kakuda TN, Schöller-Gyüre M, et al. TMC125 in combination with medications commonly used in HIV infection: summary of drug-drug interactions [poster no. S3-8]. American Conference for the Treatment of HIV (ACTHIV) 2007; 2007 May 31–Jun 3; Dallas (TX)
48.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. Pharmacokinetics (PK) of TMC125 in QD and BID regimens in HIV-1 negative volunteers [abstract no. A-1427]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
49.
Schöller-Gyüre M, Leemans R, Beets G, et al. Effect of food on the oral bioavailability of the phase III formulation of TMC125 [abstract no. 80]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr 20–22; Lisbon
50.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. Pharmacokinetics of TMC125 in HIV-negative volunteers with mild and moderate hepatic impairment [abstract no. A-1428]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
51.
Etravirine: R165335, TMC 125, TMC-125, TMC125. Drugs R & D 2006; 7 (6): 367-73
52.
Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998 Oct; 35(4): 275–91PubMedCrossRef
53.
Baede P, Piscitelli S, Graham N, et al. Drug interactions with TMC125, a potent next generation NNRTI [abstract no. A-1827]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA)
54.
van der Lee MJ, Blenke AA, Rongen GA, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007 Nov; 51(11): 4098–104PubMedCrossRef
55.
Schöller-Gyüre M, Woodfall B, Bollen S, et al. Pharmacokinetics (PK) of amprenavir (APV) and TMC125 in HIV infected volunteers receiving TMC125 with fosamprenavir/ritonavir (fosAPV/RTV) [abstract no. A-370]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
56.
McCallister S, Sabo J, Galitz L, et al. An open-label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers (BI 1182.5) [abstract no. 434]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24–28; Seattle (WA)
57.
Vourvahis M, Dumond J, Patterson K, et al. Effects of tipranavir/ritonavir on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein: implications for drug interactions [abstract no. 563]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)
58.
Schöller M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritonavir in healthy subjects [abstract no. 583]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)
59.
Harris M, Zala C, Ramirez S, et al. Pharmacokinetics and safety of adding TMC125 to stable regimens of saquinavir, lopinavir, ritonavir, and NRTI in HIV+ adults [abstract no. 575b]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)
60.
Schöller M, Hoetelmans R, Bollen S, et al. No significant interaction between TMC125 and didanosine (ddI) in healthy volunteers [abstract no. WePe3.3C16]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005 Jul 24–27; Rio de Janeiro
61.
Schöller M, Hoetelmans R, Bollen S, et al. No significant interaction between TMC125 and didanosine (ddI) in healthy volunteers [abstract no. 29]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
62.
Boffito M, Jackson A, Lamorde M, et al. Evaluation of the pharmacokinetics and safety of etravirine administered once and twice daily following two weeks of treatment with efavirenz in healthy volunteers [abstract no. H-4057]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25–28; Washington, DC
63.
Anderson MS, Kakuda TN, Miller JL, et al. Pharmacokinetic evaluation of non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and integrase inhibitor (InSTI) raltegravir (RAL) in healthy subjects [abstract no. TUPDB02]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22–25; Sydney
64.
Schöller-Gyüre M, Kakuda TN, Bollen S, et al. No pharmacokinetic interaction between TMC125 (etravirine; ETR) and paroxetine in HIV-negative volunteers [abstract no. P4.3/01]. 11th European AIDS Conference; 2007 Oct 24–27; Madrid
65.
Schöller-Gyüre M, De Smedt G, Vanaken H, et al. TMC125 bioavailability is not affected by ranitidine and omeprazole [abstract no. TUPE0082]. XVI International AIDS Conference; 2006 Aug 13–18; Toronto (ON)
66.
Eap CB, Cuendet C, Baumann P. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of α1-acid glycoprotein. Clin Pharmacol Ther 1990 Mar; 47(3): 338–46PubMedCrossRef
67.
Kharasch ED, Hoffer C, Whittington D, et al. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004 Sep; 76(3): 250–69PubMedCrossRef
68.
Schöller-Gyüre M, van den Brink W, Kakuda T, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008; 48: 322–9PubMedCrossRef
69.
70.
Schöller-Gyüre M, Debroye C, Woodfall B, et al. Pharmacokinetic interaction between TMC125 and clarithromycin [abstract no. 962]. 44th Annual Meeting of the Infectious Disease Society of America; 2006 Oct 12–15; Toronto (ON)
71.
Schöller-Gyüre M, Woodfall B, Debroye C, et al. Pharmacokinetic interaction between TMC125 and rifabutin [abstract no. 963]. 44th Annual Meeting of the Infectious Disease Society of America; 2006 Oct 12–15; Toronto (ON)
72.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitors (NNRTI) TMC 125 and atorvastatin in HIV-negative volunteers [abstract no. WEPEA 106]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22–25; Sydney
73.
74.
Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cya-noethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005 Mar 24; 48(6): 1901–9PubMedCrossRef
75.
Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278 — a novel NNRTI — in treatment-naïve HIV-1-infected subjects. AIDS 2006 Aug 22; 20(13): 1721–6PubMedCrossRef
76.
Hoetelmans R, Kestens D, Mariën K, et al. Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation: healthy volunteers [abstract no. TuPe3.1B10]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005 Jul 24–27; Rio de Janeiro
77.
Van Heeswijk R, Hoetelmans RMW, Kestens D, et al. The pharmacokinetic (PK) interaction between TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), and once daily darunavir/ritonavir (DRV/r) in HIV-negative volunteers [abstract no. H-1042]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
78.
Hoetelmans R, Kestens D, Stevens M, et al. Pharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir disoproxil fumarate (TDF) in healthy volunteers [abstract no. 18]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
79.
Van Heeswijk RPG, Hoetelmans RMW, Aharchi F, et al. The pharmacokinetic (PK) interaction between atorvastatin (AVS) and TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers [abstract no. P4.3/04]. 11th European AIDS Conference; 2007 Oct 24–27; Madrid
80.
Van Heeswijk RP, Hoetelmans RM, Kestens D, et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor in healthy, HIV-negative subjects [abstract no. TUPE0087]. 16th International AIDS Conference; 2006 August 13–18; Toronto (ON)
81.
Schöller-Gyüre M, Debroye C, Vyncke V, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI) [abstract no. 45]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr 20–22; Lisbon
82.
Van Heeswijk R, Hoetelmans R, Kestens D, et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers [abstract no. TUPDB01]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 July 22–25; Sydney
83.
84.
Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 Nov; 49(11): 4721–32PubMedCrossRef
85.
Hyland R, Jones B, Muirhead G. In vitro assessment of the CYP-based drug-drug interaction potential of UK-427,857 [poster no. 5.9]. 5th International Workshop on the Clinical Pharmacology of HIV Therapy; 2004 Mar 11–13; Rome
86.
Abel S, Russell D, Ridgway C, et al. The effect of CCR5 antagonist UK-427,857, on the pharmacokinetics of CYP3A4 substrates in healthy volunteers [poster no. 5.7]. 5th International Workshop on the Clinical Pharmacology of HIV Therapy; 2004 Mar 11–13; Rome
87.
Abel S, Russell D, Whitlock LA, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 19–26PubMedCrossRef
88.
Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005 Apr; 33(4): 587–95PubMedCrossRef
89.
90.
91.
Abel S, Russell D, Whitlock LA, et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 60–7PubMedCrossRef
92.
Abel S, Van der Ryst E, Muirhead GJ, et al. Pharmacokinetics of single and multiple oral doses of UK-427,857 — a novel CCR5 antagonist in healthy volunteers [abstract no. 547]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston (MA)
93.
Abel S, van der Ryst E, Rosario MC, et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 5–18PubMedCrossRef
94.
Russell D, Ridgway C, Taylor-Worth R, et al. Pharmacokinetics special populations and toxicity comparison of the pharmacokinetics of maraviroc (UK-427,857) in healthy Asian and Caucasian subjects [abstract no. 41]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
95.
Abel S, Ridgway C, Hamlin J, et al. An open, parallel group study to compare the pharmacokinetics, safety and toleration of a single oral dose of mar-aviroc in subjects with mild and moderate hepatic impairment with subjects with normal hepatic function [abstract no. 8]. 8th International Workshop on Pharmacology of HIV Therapy; 2007 Apr 16–18; Budapest
96.
Muirhead G, Pozniak A, Gazzard B, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of UK-427,857 in HIV +ve subjects [abstract no. 663]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Apr 22–25; Boston (MA)
97.
Pozniak AL, Boffito M, Russell D, et al. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 54–9PubMedCrossRef
98.
Abel S, Russell C, Ridgway C, et al. The effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857, in healthy volunteers [poster no. 5.8]. 5th International Workshop on the Clinical Pharmacology of HIV Therapy; 2004 Mar 11–13; Rome
99.
Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 27–37PubMedCrossRef
100.
Muirhead G, Ridgway C, Leahy D, et al. A study to investigate the combined coadministration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract no. P284]. 7th International Congress on Drug Therapy for HIV; 2004 Nov 14–18; Glasgow
101.
Abel S, Jenkins TM, Whitlock LA, et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 38–46PubMedCrossRef
102.
Abel S, Taylor-Worth R, Ridgway C, et al. Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK 427,857) in healthy volunteers [abstract no. LBPE4.3/15]. 10th European AIDS Conference; 2005 Nov 17–20; Dublin
103.
Muirhead G, Abel S, Russell D, et al. An investigation of the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract no. P283]. 7th International Congress on Drug Therapy for HIV; 2004 Nov 14–18; Glasgow
104.
Russell D, Abel S, Hackman F, et al. The effect of maraviroc (UK-427,857) on the pharmacokinetics of 3TC/AZT (Combivir™) in healthy subjects [abstract no. 30]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
105.
Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857, in healthy volunteers [poster no. 5.4]. 5th International Workshop on the Clinical Pharmacology of HIV Therapy; 2004 Mar 11–13; Rome
106.
Davis J, Schöller-Gyüre M, Kakuda TN, et al. An open, randomized, two-period, crossover study in 2 cohorts to investigate the effect of steady-state TMC125 and the combination of TMC125/darunavir/ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects [abstract no. P4.3/02]. 11th European AIDS Conference/EACS; 2007 Oct 24–27; Madrid
107.
Ramanathan S, West S, Abel S, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir plus maraviroc [abstract no. H-1050]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
108.
Andrews E, Glue P, Labadie R, et al. A pharmacokinetic (PK) study to evaluate an interaction between maraviroc (MVC) and raltegravir (RAL) in healthy adults [abstract no. H-4055]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/IDSA 46th Annual Meeting; 2008 Oct 25–28; Washingtion, DC
109.
110.
Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005 Dec; 49(12): 4911–9PubMedCrossRef
111.
Ghosal A, Ramanathan R, Yuan Y, et al. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos 2007 Dec; 35(12): 2186–95PubMedCrossRef
112.
Li C, Keung A, Morrison RA, et al. Vicriviroc, a novel CCR5 inhibitor, is not a P-glycoprotein substrate in vitro. Retrovirology 2005; 2 Suppl. 1: P1–58
113.
Schürmann D, Fätkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007 Jun 19; 21(10): 1293–9PubMedCrossRef
114.
Keung A, Sansone A, Caceres M, et al. Effect of food on bioavailability of SCH 417690 in healthy volunteers [abstract no. A-1200]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16–19; Washington, DC
115.
Sansone A, Seiberling M, Kraan M, et al. Similar increase in SCH 417690 plasma exposure with coadministration of varying doses of ritonavir in healthy volunteers [abstract no. 78]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
116.
Sansone A, Keung A, Tetteh E, et al. Pharmacokinetics of vicriviroc are not affected in combination with five different protease inhibitors boosted by ritonavir [abstract no. 582]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)
117.
Sansone A, Saltzman M, Rosenberg M, et al. Pharmacokinetics of new drugs pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir or lopinavir/ritonavir [abstract no. 83]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
118.
Sansone-Parsons A, Keung A, Caceres M, et al. The addition of tipranavir has no impact on the pharmacokinetics of vicriviroc when coadministered with a potent CYP3A4 inhibitor such as ritonavir [abstract no. 57]. 8th International Workshop on Pharmacology of HIV Therapy; 2007 Apr 16–18; Budapest
119.
Sansone A, Guillaume M, Kraan M, et al. The pharmacokinetics of SCH 417690 when administered alone and in combination with lamivudine/zidovudine [abstract no. 84]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
120.
Sansone A, Guillaume M, Kraan M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with tenofovir [abstract no. 85]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
121.
Sansone A, Saltzman M, Rosenberg M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers [abstract no. 79]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec City (QC)
122.
Shin N, Solomon K, Wang KH, et al. INCB 9471 is a non-competitive small molecule antagonist of CCR5 [abstract no. H-1032]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
123.
Cohen C, DeJesus E, Mills A, et al. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days of monotherapy [abstract no. TUAB106]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 July 22–25; Sydney
124.
Troy S, Emm T, Yeleswaram S, et al. Single and multiple dose pharmacokinetics of INCB009471: a potent antagonist of CCR5 co-receptor [abstract no. H-1034]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
125.
Troy S, Emm T, Yeleswaram S, et al. Effect of ritonavir on the pharmacokinetics of INCB009471: a potent antagonist of the CCR5 co-receptor [abstract no. H-1035]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
126.
127.
Roquebert B, Damond F, Collin G, et al.; The French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors: raltegravir and elvitegravir [abstract no. 83]. Antivir Ther 2007; 12: S92
128.
Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007 Sep; 9(35): 1657–63CrossRef
129.
Petry AS, Wenning LA, Laethem M, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-0518 in healthy subjects [abstract no. A-376]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
130.
Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006 Dec 15; 43(5): 509–15PubMedCrossRef
131.
Wenning L, Anderson M, Petry A, et al. Raltegravir (RAL) dose proportionality and effect of food [abstract no. H-1046]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
132.
Iwamoto M, Hanley W, Petry A, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother. Epub 2009 Feb 17
133.
Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007 Jun; 27(6): 888–909PubMedCrossRef
134.
Iwamoto M, Wenning LA, Petry AS, et al. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of Mk-0518 [abstract no. A-373]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
135.
Wenning LA, Hanley H, Stone J, et al. Effect of tipranavir + ritonavir TPV + RTV on pharmacokinetics of MK-0518 [abstract no. A-374]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
136.
137.
Kumar P, Cooper D, Steigbigel R, et al. Efficacy of raltegravir, an HIV integrase inhibitor, in combination with regimens containing-efuvirtide, darunavir, or tipranavir in patients with triple-class resistant virus: combined results from BENCHMRK-1 and BENCHMRK-2 [abstract no. P7.2/06]. 11th European AIDS Conference/EACS; 2007 Oct 24–27; Madrid
138.
Wenning LA, Friedman E, Kost JT, et al. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF) [abstract no. A-375]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco, (CA)
139.
Iwamoto M, Wenning L, Petry A, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2008; 52(12): 4338–43PubMedCrossRef
140.
Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008 Feb; 48(2): 209–14PubMedCrossRef
141.
Iwamoto M, Wenning LA, Liou SY, et al. Rifampin (RIF) modestly reduces plasma levels of MK-0518 [abstract no. P299]. 8th International Congress on Drug Therapy for HIV; 2006 Nov 12–16; Glasgow
142.
Anderson MS, Wenning LA, Moreau A, et al. Effect of raltegravir (RAL) on the pharmacokinetics (PK) of oral contraceptives [abstract no. A-1425]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago
143.
144.
Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. J Acquir Immune Defic Syndr 2007 Oct 1; 46(2): 160–6PubMedCrossRef
145.
DeJesus E, Berger D, Markowitz M, et al., for the 183-0101 Study Team. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J Acquir Immune Defic Syndr 2006 Sep; 43(1): 1–5PubMedCrossRef
146.
Kawaguchi I, Ishikawa T, Ishibashi M, et al. Safety and pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–9; San Francisco (CA)
147.
Mathias A, Hinkle J, Enejosa J, et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and tipranavir/r [abstract no. TUPDB06]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22–25; Sydney
148.
Mathias A, Shen G, Enejosa J, et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and darunavir/r [abstract no. TUPDB03]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22–25; Sydney
149.
150.
151.
Ramanathan S, Skillington J, Plummer A, et al. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (GS-9137/r) and emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF) [abstract no. TUPE0080]. XVI International AIDS Conference; 2006 Aug 13–18; Toronto (ON)
152.
Ramanathan S, Lagan K, Plummer A, et al. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents [abstract no. 69]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16–18; Budapest
153.
Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003 Nov 11; 100(23): 13555–60PubMedCrossRef
154.
Martin DE, Blum R, Wilton J, et al. Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 2007 Sep; 51(9): 3063–6PubMedCrossRef
155.
Martin DE, Smith P, Wild CT, et al. In vitro and in vivo disposition of PA-457, a novel inhibitor of HIV-1 maturation [abstract no. WePeA5644]. XV International AIDS Conference; 2004 Jul 11–16; Bangkok
156.
Martin DE, Blum R, Doto J, et al. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet 2007; 46(7): 589–98PubMedCrossRef
157.
Martin DE, Smith P, Goila-Gaur R, et al. Determinants of activity, in vitro metabolism and in vivo disposition of the novel maturation inhibitor PA-457 [abstract no. 545]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco (CA)
158.
Smith P, Forrest A, Beatty G, et al. Pharmacokinetics/pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV infected patients [abstract no. 52]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)
159.
Martin D, Galbraith H, Ellis C, et al. Minimal effect of ritonavir (RTV) on the pharmacokinetics (PK) of bevirimat (BVM) in healthy volunteers [abstract no. WEPEB015]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22–25; Sydney
160.
Martin DE, Gailbraith H, Schettler J, et al. Lack of a PK/PD interaction between PA-457 and atazanavir (ATV) in healthy volunteers [abstract no. A-377]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)
161.
de Béthune M-P, Andries K, Azijn H, et al. TMC278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile [abstract no. 556]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)
162.
Petry AS, Hanley WD, Silk G, et al. Effect of severe renal insufficiency on raltegravir (RAL) pharmacokinetics [abstract no. A-1424]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
Metadata
Title
Drug Interactions with New and Investigational Antiretrovirals
Authors
Kevin C. Brown
Sunita Paul
Dr Angela D. M. Kashuba
Publication date
01-04-2009
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 4/2009
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200948040-00001

Other articles of this Issue 4/2009

Clinical Pharmacokinetics 4/2009 Go to the issue

Original Research Article

Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates

Original Research Article

Vancomycin Dosage Optimization in Patients with Malignant Haematological Disease by Pharmacokinetic/Pharmacodynamic Analysis

Original Research Article

Pharmacokinetics and Safety of Intrathecal Liposomal Cytarabine in Children Aged <3 Years

Review Article

Clinical Pharmacokinetic and Pharmacodynamic Profile of Inhaled Ciclesonide